Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• BRAF mutations are prevalent in various cancers, including melanoma and thyroid carcinoma.
• These mutations serve as crucial markers for diagnosis, prognosis, and predicting treatment response.
• There is a need for sensitive, specific, and cost-effective assays to detect BRAF mutations.

Purpose of the Study:

• To develop and validate a novel assay for detecting the BRAF V600E mutation.
• To assess the sensitivity and specificity of the developed assay in formalin-fixed, paraffin-embedded (FFPE) tissues.
• To compare the performance of the new assay with existing methods like dideoxy sequencing.

Main Methods:

• Developed an Amplification Refractory Mutation System (ARMS)-PCR method.
• The assay amplifies three products in a single tube: a common control, a BRAF V600E specific product, and a wild-type specific product.
• Validated the method in 72 thyroid tumors and compared it with direct dideoxy sequencing.

Main Results:

• The ARMS-PCR method demonstrated a sensitivity as low as 0.5% for the BRAF V600E allele.
• The assay successfully identified BRAF V600E mutations in 67% of conventional papillary thyroid carcinomas and 75% of tall-cell variant PTC.
• ARMS-PCR showed higher sensitivity compared to dideoxy sequencing in detecting low BRAF V600E allele burdens.

Conclusions:

• The developed ARMS-PCR method is a rapid and sensitive tool for detecting BRAF V600E mutations in FFPE tumor specimens.
• This ARMS-PCR assay is more sensitive than automated dideoxy sequencing for low-level BRAF V600E mutations.
• The ARMS-PCR strategy can be adapted for detecting point mutations in other biomarker genes for early disease detection.